You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data

GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced yesterday.